Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-26T05:21:41.180Z Has data issue: false hasContentIssue false
  • English
  • Français

Intra-Arterial vs Intra-Venous Thrombolysis for Anterior Cerebral Occlusion

Published online by Cambridge University Press:  02 December 2014

Bin Zhang ,
Xiaojiang Sun ,
Minghua Li ,
Feng Wang ,
Dan Xu ,
Hao Duan  and
Chun Fang
Bin Zhang
Affiliation:
Department of Neurology and Neurobiology Laboratory
Xiaojiang Sun*
Affiliation:
Department of Neurology and Neurobiology Laboratory
Minghua Li
Affiliation:
Department of Radiology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
Feng Wang
Affiliation:
Department of Neurology and Neurobiology Laboratory
Dan Xu
Affiliation:
Department of Neurology and Neurobiology Laboratory
Hao Duan
Affiliation:
Department of Neurology and Neurobiology Laboratory
Chun Fang
Affiliation:
Department of Radiology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
*
Department of Neurology and Neurobiology Laboratory, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, No 600, Yishan Road, Shanghai 200233, China.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The safety and effectiveness of intra-arterial thrombolysis (IAT) in comparison to intravenous thrombolysis (IVT) for the treatment of ischemic stroke is uncertain. Our study aims to assess and compare IAT to IVT for clinically relevant outcomes in patients with occlusion of the anterior cerebral circulation.

Methods:

Patients with acute ischemic stroke were enrolled for either treatment; those whose symptoms occurred within 4.5 hrs after stroke were treated with IVT, whereas those who presented <4.5 hrs but had contraindications to IVT or presented between 4.5 and 6 hrs were treated with IAT. Evaluated endpoints included: disability at 90 days as measured by the modified Rankin Scale (mRS), incidence of mortality, and incidence of symptomatic intracranial haemorrhage.

Results:

78 patients with anterior cerebral circulation occlusion were included in the study (55 in IVT, 23 in IAT). After 90 days, 82.6% patients treated with IAT reached independence in comparison to 56.4% in the IVT group (P=0.028, RR=2.66, 95% CI: 1.10-7.04). The incidence of all intracranial haemorrhages in the IAT and IVT groups respectively were 30.4% and 12.7% (P=0.103, RR=2.391, 95% CI: 0.946-6.047); symptomatic intracranial haemorrhage occurred in 8.7% and 9.1% of patients (P=1.00, RR= 0.957, 95% CI: 0.200-4.579), and mortality in 8.7% and 16.4% (P=0.492, RR=1.882, 95% CI: 0.440-8.045).

Conclusion:

Results suggest that IAT is more effective than IVT in allowing patients to achieve independence. While inconclusive, the safety of IAT within 6 hrs is comparable to IVT within 4.5 hrs.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 37 , Issue 2 , March 2010 , pp. 240 - 244
Copyright
Copyright © The Canadian Journal of Neurological 2010

References

1. The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.Google Scholar
2. Hacke, W, Bluhmki, E, Steiner, T, Tatlisumak, T, Mahagne, MH, Sacchetti, ML, et al. Dichotomized efficacy end points and global end-point analysis applied to the ECASS Intention-to-Treat Data Set: post hoc analysis of ECASS I. Stroke. 1998;29:2073–5.Google Scholar
3. Hacke, W, Bluhmki, E, Steiner, T, Tatlisumak, T, Mahagne, MH, Sacchetti, ML, et al. Randomised double-blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245–51.Google Scholar
4. Albers, GW, Bates, VE, Clark, WM, Bell, R, Verro, P, Hamilton, SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145–50.Google Scholar
5. Albers, GW, Clark, WM, Madden, KP, Hamilton, SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Stroke. 2002;33:493–5.Google Scholar
6. Hacke, W, Donnan, G, Fieschi, C, Kaste, M, von Kummer, R, Broderick, JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.Google Scholar
7. Hacke, W, Kaste, M, Bluhmki, E, Brozman, M, Dávalos, A, Guidetti, D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.Google Scholar
8. Wahlgren, N, Ahmed, N, Dávalos, A, Hacke, W, Millán, M, Muir, K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372 9646:1303–9.Google Scholar
9. Lisboa, RC, Jovanovic, BD, Alberts, MJ. Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. Stroke. 2002;33:2866–71.Google Scholar
10. Furlan, A, Higashida, R, Wechsler, L, Gent, M, Rowley, H, Kase, C, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: prolyse in acute cerebral thromboembolism. JAMA. 1999;282:2003–11.CrossRefGoogle ScholarPubMed
11. del Zoppo, GJ, Poeck, K, Pessin, MS, Wolpert, SM, Furlan, AJ, Ferbert, A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;(32):78–86.Google Scholar
12. Macleod, MR, Davis, SM, Mitchell, PJ, Gerraty, RP, Fitt, G, Hankey, GJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis. 2005;20:12–7.Google Scholar
13. Ezaki, Y, Tsutsumi, K, Onizuka, M, Kawakubo, J, Yagi, N, Shibayama, A, et al. Retrospective analysis of neurological outcomes after intra-arterial thrombolysis in basilar artery occlusion. Surg Neurol. 2003;60:423–30.CrossRefGoogle ScholarPubMed
14. Mielke, O, Wardlaw, J, Liu, M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;18(4):CD000514.Google Scholar
15. Agarwal, P, Kumar, S, Hariharan, S, Eshkar, N, Verro, P, Cohen, B, et al. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis. 2004;17(2-3):182–90.Google Scholar
16. Intraarterial thrombolysis: ready for prime time? Executive Committee of the ASITN. AJNR Am J Neuroradiol. 2001;22(1):55–8.Google Scholar
17. Mattle, HP, Arnold, M, Georgiadis, D, Baumann, C, Nedeltchev, K, Benninger, D, et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke. 2008;39:379–83.Google Scholar
18. Alexandrov, AV, Black, SE, Ehrlich, LE, Caldwell, CB, Norris, JW. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke. 1997;28:1198–202.CrossRefGoogle ScholarPubMed
19. Toni, D, Fiorelli, M, Bastianello, S, Sacchetti, ML, Sette, G, Argentino, C, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology. 1996;46:341–5.Google Scholar
20. Molina, CA, Montaner, J, Abilleira, S, Ibarra, B, Romero, F, Arenillas, JF, et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke. 2001;32:1079–84.Google Scholar
21. Molina, CA, Alvarez-Sabín, J, Montaner, J, Abilleira, S, Arenillas, JF, Coscojuela, P, et al. Thrombolysis-related hemorrhagic infarction. Stroke. 2002;33:1551–6.Google Scholar
22. Neumann-Haefelin, T, du Mesnil de Rochemont, R, Fiebach, JB, Gass, A, Nolte, C, Kucinski, T, et al. Effect of incomplete (Spontaneous and Postthrombolytic) recanalization after middle cerebral artery occlusion. A magnetic resonance imaging study. Stroke. 2004;35:109–14.CrossRefGoogle ScholarPubMed
23. The IMS Study Investigators. Haemorrhage in the interventional management of stroke study. Stroke. 2006;37:847–51.Google Scholar
24. IMS Trial Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke. 2004;35:904–11.Google Scholar